Medpace (MEDP) to Release Earnings on Wednesday

Key Points

• Q1 2026 earnings are due after the market close on Wednesday, April 22; analysts expect $3.74 EPS and ~$697.8M revenue, and Medpace has set FY2026 guidance of $16.68–$17.50 EPS.
• In the prior quarter Medpace beat estimates with $4.67 EPS (vs. $4.18 est.) and $708.45M revenue (+32% y/y), and analysts forecast roughly $12 EPS for the current fiscal year and $14 EPS for the next.
• Risks include a large insider sale—President Jesse J. Geiger sold 31,707 shares (~$14.4M, cutting his stake by ~67.9%)—and multiple class-action lawsuits alleging securities-law violations that could create legal and reputational exposure.

Medpace (NASDAQ:MEDP - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect Medpace to post earnings of $3.74 per share and revenue of $697.8220 million for the quarter. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, April 23, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the firm earned $3.67 earnings per share. The business's quarterly revenue was up 32.0% compared to the same quarter last year. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Stock Performance

Shares of MEDP opened at $520.00 on Wednesday. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The company has a market capitalization of $14.85 billion, a price-to-earnings ratio of 33.99, a price-to-earnings-growth ratio of 2.40 and a beta of 1.39. The firm has a 50-day simple moving average of $470.19 and a 200-day simple moving average of $537.96.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company's stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Mcguire Capital Advisors Inc. purchased a new position in Medpace in the fourth quarter valued at about $66,000. Axxcess Wealth Management LLC increased its holdings in Medpace by 503.7% in the fourth quarter. Axxcess Wealth Management LLC now owns 4,063 shares of the company's stock valued at $2,282,000 after buying an additional 3,390 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Medpace by 26.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 28,064 shares of the company's stock valued at $15,762,000 after buying an additional 5,840 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in Medpace in the fourth quarter valued at about $281,000. Finally, Fuller & Thaler Asset Management Inc. grew its position in shares of Medpace by 5.3% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 76,877 shares of the company's stock valued at $43,178,000 after purchasing an additional 3,847 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on MEDP shares. TD Cowen upgraded shares of Medpace from a "sell" rating to a "hold" rating and decreased their target price for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Barclays upgraded shares of Medpace from an "underweight" rating to an "equal weight" rating and set a $500.00 target price for the company in a research note on Friday, March 6th. Jefferies Financial Group upgraded shares of Medpace from a "hold" rating to a "buy" rating and set a $560.00 target price for the company in a research note on Friday, February 13th. Royal Bank Of Canada started coverage on shares of Medpace in a research note on Tuesday, March 3rd. They set an "outperform" rating and a $522.00 target price for the company. Finally, Mizuho set a $582.00 target price on shares of Medpace in a research note on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Medpace presently has an average rating of "Hold" and an average target price of $486.67.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Recent fundamentals support the rally: Medpace reported a clear beat on the last quarterly report (Q: $4.67 EPS vs. $4.18 est.; revenue $708.5M, +32% y/y) and set FY2026 EPS guidance of $16.68–$17.50 — factors that improve near-term earnings visibility and likely underpin buying interest.
• Neutral Sentiment: Market commentary notes MEDP has recently outpaced the broader market, reflecting investor focus on the company's growth metrics and margins. Read More.
• Negative Sentiment: Multiple law firms have announced class actions or investor-alerts alleging securities-law violations covering purchases from April 22, 2025 to February 9, 2026; firms are soliciting plaintiffs and flagging June lead-plaintiff/filing deadlines — this creates reputational and potential financial risk (defense costs, settlements) and can pressure the stock until the litigation path clears. Examples: Read More., Read More., Read More., Read More., Read More..

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.